World Investment Advisors grew its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 5.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 167,403 shares of the medical technology company’s stock after acquiring an additional 8,961 shares during the quarter. World Investment Advisors’ holdings in Medtronic were worth $16,081,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Medtronic by 3,424.7% during the 2nd quarter. Marshall Wace LLP now owns 160,374 shares of the medical technology company’s stock worth $13,980,000 after buying an additional 155,824 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Medtronic during the 2nd quarter worth $299,000. Finally, Baker Avenue Asset Management LP raised its holdings in shares of Medtronic by 15.4% during the 2nd quarter. Baker Avenue Asset Management LP now owns 5,260 shares of the medical technology company’s stock worth $458,000 after buying an additional 702 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.
More Medtronic News
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Market reports highlight long-term demand growth in segments where Medtronic competes (anesthesia & respiratory devices; lung cancer surgery), supporting structural revenue tailwinds for MDT. Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035
- Positive Sentiment: Healthcare market analysis cites rising adoption of minimally invasive and robotic-assisted technologies — a growth area that includes Medtronic’s surgical portfolio. Global Lung Cancer Surgery Market | Rise at 5.9% CAGR
- Positive Sentiment: Several sell‑side firms (Citigroup, Evercore, Argus) cut price targets but maintained Buy/Outperform ratings, indicating confidence in MDT’s long‑term fundamentals despite near‑term modeling changes. Evercore Adjusts Medtronic Price Target to $108
- Neutral Sentiment: Headline market activity lifted NYSE-listed names, including MDT — broader market moves are contributing to today’s modest uptick rather than company‑specific news. Medtronic plc Climbs As NYSE Composite Shows Market Activity
- Neutral Sentiment: Comparative financial write‑ups (OMER vs MDT; MGNX vs MDT) provide investor context but contain no new MDT‑specific catalysts. Omeros and Medtronic Financial Review MacroGenics vs. Medtronic Financial Comparison
- Negative Sentiment: Stifel lowered its price target to $95 and reiterated a Hold, explicitly citing transaction‑related impacts from the MiniMed diabetes IPO / spin‑off as limiting near‑term upside; this is a direct headwind for sentiment. Stifel Cuts MDT Target to $95, Cites MiniMed IPO Effects
- Negative Sentiment: Analyst notes and coverage (TipRanks, Stifel commentary) emphasize that the MiniMed IPO/dilution and the diabetes spin‑off could cap near‑term stock appreciation, reinforcing cautious ratings. Medtronic: MiniMed IPO Dilution and Diabetes Spin-Off Limit Near-Term Upside
- Negative Sentiment: Competitive news: J&J launched an enhanced pulsed‑field ablation (PFA) platform in Europe — a potential competitive pressure in cardiac electrophysiology markets where Medtronic also competes. J&J launches enhanced PFA device in Europe
Insider Activity at Medtronic
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Sanford C. Bernstein boosted their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Evercore lowered their price target on Medtronic from $115.00 to $108.00 and set an “outperform” rating for the company in a report on Monday. UBS Group reissued a “neutral” rating and set a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Finally, Mizuho raised Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.10.
Check Out Our Latest Report on Medtronic
Medtronic Price Performance
Shares of MDT opened at $86.40 on Wednesday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The business has a 50-day simple moving average of $93.90 and a two-hundred day simple moving average of $96.13. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market cap of $110.92 billion, a PE ratio of 24.07, a PEG ratio of 2.24 and a beta of 0.75.
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.
Medtronic Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is 79.11%.
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Recommended Stories
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
